Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice Ornella LetariCatherine BoothGianfranco Caselli Original Article Open access 30 December 2009 Pages: 819 - 827
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer A. SabharwalP. G. CorrieM. R. Middleton Original Article 29 December 2009 Pages: 829 - 835
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study Salvatore Del PreteLiliana MontellaRaffaele Addeo Original Article 30 December 2009 Pages: 837 - 844
A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group M. M. MooreM. StocklerM. J. Boyer Original Article 16 January 2010 Pages: 845 - 850
Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action Yi ZhangHongyan LiXiaoguang Chen Original Article 06 January 2010 Pages: 851 - 859
A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer Jalid SehouliOumar CamaraGuelten Oskay-Oezcelik Original Article 07 January 2010 Pages: 861 - 868
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo Scott AcklerMichael J. MittenAlexander R. Shoemaker Original Article 23 January 2010 Pages: 869 - 880
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo Caroline D. ScatenaJeffrey L. KumerJeffrey A. Silverman Original Article 08 January 2010 Pages: 881 - 888
Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer Jung Hye KwonJung Han KimDae Young Zang Original Article 21 January 2010 Pages: 889 - 897
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α Sreenivasulu ChintalaKároly TόthYoucef M. Rustum Original Article 12 January 2010 Pages: 899 - 911
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer Kazuhiro YanagiharaKenichi YoshimuraMasanori Fukushima Original Article 13 January 2010 Pages: 913 - 918
A general process for the development of peptide-based immunoassays for monoclonal antibodies Ana B. SanchezTammy NguyenBradley T. Messmer Original Article Open access 20 January 2010 Pages: 919 - 925
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors Robert J. MorganTimothy SynoldJames H. Doroshow Original Article 28 January 2010 Pages: 927 - 933
Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors Yasuhito FujisakaYasuhide YamadaMitsuo Seki Original Article 28 January 2010 Pages: 935 - 943
Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression Dilip JainNila PatelWolfram Siede Original Article 26 January 2010 Pages: 945 - 952
Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of Nitidine Hironori IwasakiTakafumi OkabeHirosuke Oku Original Article 18 March 2010 Pages: 953 - 959
Phase II study of pemetrexed in patients with advanced neuroendocrine tumors Jennifer A. ChanAndrew X. ZhuMatthew H. Kulke Original Article 04 February 2010 Pages: 961 - 968
Increased anticoagulant activity of warfarin used in combination with doxifluridine Masaru NakajimaTomoo GendaYasufumi Sawada Original Article 28 January 2010 Pages: 969 - 972
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors Brian S. ChoiDona B. AlbertiKyle D. Holen Original Article 02 February 2010 Pages: 973 - 980
Antitumor effects of recombinant human Interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis Chuan-gang LiMo-lin LiWen-sen Wu Original Article 25 May 2010 Pages: 981 - 986
A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer Manabu ShiozawaMakoto AkaikeSoichiro Morinaga Clinical Trial Report 10 July 2010 Pages: 987 - 992
Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients Franca FormelliElena CavadiniStefano Persiani Short Communication 08 June 2010 Pages: 993 - 998
C6 ceramide potentiates curcumin-induced cell death and apoptosis in melanoma cell lines in vitro Teng YuJinchao LiHui Sun Short Communication 03 June 2010 Pages: 999 - 1003